How GLP-1 Drugs Protect the Kidneys: From Molecules to Clinical Evidence
GLP-1 receptor agonists protect kidneys through anti-inflammatory, antioxidant, and anti-fibrotic pathways, confirmed by the landmark FLOW trial with semaglutide.
Quick Facts
What This Study Found
GLP-1 receptor agonists protect kidneys through anti-inflammatory, antioxidant, and anti-fibrotic mechanisms, with clinical data from the FLOW trial confirming semaglutide slows kidney disease progression.
Key Numbers
The FLOW study tested semaglutide 1 mg vs. placebo. Recruitment ran from 2019 to May 2021. GLP-1 drugs were first introduced for diabetes in 2005 and obesity in 2014.
How They Did This
Pharmacophysiological review combining molecular mechanisms with clinical trial evidence.
Why This Research Matters
Chronic kidney disease affects hundreds of millions of people worldwide and has limited treatment options. Showing that GLP-1 drugs protect kidneys adds a major benefit beyond their effects on blood sugar and weight.
The Bigger Picture
Chronic kidney disease affects hundreds of millions worldwide with limited treatment options. GLP-1 drugs join SGLT2 inhibitors and finerenone as kidney-protective agents, giving nephrologists more tools.
What This Study Doesn't Tell Us
This is a review article synthesizing existing data. The kidney-protective mechanisms described are based partly on animal and cell studies.
Questions This Raises
- ?Can GLP-1 drugs and SGLT2 inhibitors be combined for additive kidney protection?
- ?Do all GLP-1 drugs provide equal kidney benefit?
Trust & Context
- Key Stat:
- FLOW trial confirms benefit The FLOW trial provided definitive clinical evidence that semaglutide slows kidney disease progression in type 2 diabetes
- Evidence Grade:
- Rated strong: comprehensive review combining molecular mechanisms with clinical trial evidence, including the landmark FLOW trial.
- Study Age:
- Published in 2024. Includes FLOW trial results, making this one of the most current kidney protection reviews.
- Original Title:
- Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.
- Published In:
- Jornal brasileiro de nefrologia, 46(4), e20240101 (2024)
- Authors:
- Rico-Fontalvo, Jorge(2), Reina, Maricely, Soler, María José(2), Unigarro-Palacios, Mario, Castañeda-González, Juan Pablo, Quintero, Javier Jiménez, Raad-Sarabia, María, Moraes, Thyago Proença de, Daza-Arnedo, Rodrigo
- Database ID:
- RPEP-09147
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do GLP-1 drugs protect the kidneys?
Yes — the FLOW trial proved semaglutide slows kidney disease progression. The protection comes from anti-inflammatory, antioxidant, and anti-scarring effects.
Should diabetic kidney disease patients take semaglutide?
Based on the FLOW trial, semaglutide provides significant kidney protection in patients with type 2 diabetes and chronic kidney disease.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09147APA
Rico-Fontalvo, Jorge; Reina, Maricely; Soler, María José; Unigarro-Palacios, Mario; Castañeda-González, Juan Pablo; Quintero, Javier Jiménez; Raad-Sarabia, María; Moraes, Thyago Proença de; Daza-Arnedo, Rodrigo. (2024). Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.. Jornal brasileiro de nefrologia, 46(4), e20240101. https://doi.org/10.1590/2175-8239-JBN-2024-0101en
MLA
Rico-Fontalvo, Jorge, et al. "Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective.." Jornal brasileiro de nefrologia, 2024. https://doi.org/10.1590/2175-8239-JBN-2024-0101en
RethinkPeptides
RethinkPeptides Research Database. "Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molec..." RPEP-09147. Retrieved from https://rethinkpeptides.com/research/rico-fontalvo-2024-kidney-effects-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.